Notice Number: NOT-HD-13-008
Update: The following update relating to this announcement has been issued:
- August 23, 2013 - See Notice NOT-HD-13-012. Notice Providing Information about the Availability of Embryonic Lethal and Sub-Viable Knockout Mouse Strains for Applicants.
Key Dates
Release Date: June 5, 2013
PAR-13-231
NOT-HD-14-021
NOT-HD-13-012
Issued by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Purpose
The purpose of this Notice is to provide additional information for applicants interested in responding to PAR-13-231 which encourages R01 applications to phenotype embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.
Potential applicants may get information from the IMPC website on the status of the KO mouse pipeline, the phenotyping protocols, and the availability of embryonic lethal strains at www.mousephenotype.org. They also may browse the gene list, register to receive gene status updates, and examine the phenotype protocols at this site.
Another site for information on the availability of resources is the KOMP Repository at https://www.komp.org/.
In developing R01 applications to this FOA, access to mouse strains as well as potential collaborations may be discussed with the three NIH-funded KOMP2 Phenotyping Centers that are identifying and generating the embryonic lethal mouse strains:
The BaSH Consortium (Baylor College of Medicine; the Mouse Genetics Programme at the Wellcome Trust Sanger Institute; and, the Medical Research Council at Harwell, UK)
Contact: Mary Dickinson at [email protected]
The DTCC Consortium (University of California, Davis; Toronto Centre for Phenogenomics; Children’s Hospital Oakland Research Institute; and, Charles River Laboratories)
Contact: Kent Lloyd at [email protected]
The Jackson Laboratory
Contact: Steve Murray or Karen Svenson at [email protected]
As a reminder to applicants and as stated in the FOA, an important aspect of secondary and tertiary tier screening of embryonic lethal mouse lines will be the integration of phenotypic data into the exiting database supported by the IMPC. It is strongly suggested that investigators submitting R01 applications to this FOA develop a data management and data sharing strategy in consultation with the IMPC data coordinating center led by the KOMP2 Mouse Phenotyping Informatics Infrastructure (MPI2) Consortium (the European Bioinformatics Institute, the Medical Research Council at Harwell, and the Wellcome Trust Sanger Institute). Funds associated with data management and data deposition may be requested with appropriate justification. The data coordinating center may be contacted at [email protected]. Please use NIH PAR-13-231 as the subject line of your email.
All other aspects of the FOA remain unchanged.Inquiries
Please direct all inquiries to:
Lorette C. Javois, Ph.D.
Developmental Biology and Structural Variation Branch
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-496-5541
Email: [email protected]
Website: http://www.nichd.nih.gov/about/org/der/branches/dbsvb/Pages/overview.aspx
and Human Services (HHS)
